Literature DB >> 31187710

System Bioinformatic Approach Through Molecular Docking, Network Pharmacology and Microarray Data Analysis to Determine the Molecular Mechanism Underlying the Effects of Rehmanniae Radix Praeparata on Cardiovascular Diseases.

Xiang Zhang1, Dongdong Wang2,3, Xiaodong Ren4, Atanas G Atanasov2,3, Rui Zeng5, Linfang Huang1.   

Abstract

Cardiovascular diseases (CVDs) are the leading cause of mortality worldwide. Rehmanniae Radix Praeparata (RRP) is a popular medicinal herb widely used in traditional Chinese medicine (TCM) to treat CVDs. However, the development of this novel therapeutic product has been stagnant, and its molecular mechanism of action remains unclear. This study aims to explore the effective ingredients of RRP against CVDs, especially atherosclerosis (AS). Using the AutoDock Vina software, the RRP's ingredients were docked with the targets which can be collected by RCSB and UniProt. Then the screened ingredients and targets could be used to dispose the pathways by the Kyoto Encyclopedia of Genes and Genomes (KEGG). We used GEO, GCBI and DAVID databases to analyze the microarray data of AS which could be used to verify the results of molecular docking, all of which could show the molecular mechanism of RRP on CVDs. We also constructed a compound-target interaction network of CVD with 85 nodes and 272 edges on the basis of molecular docking analysis through Cytoscape. The network showed that forsythiaside, acteoside and stigmasterol are the most important compounds and 2HRR (ACAT (Acyl-CoA cholesterol acyl transferase) protein), 4ATB (MMP13) and 1JBQ (cystathionine beta-synthase) are the most valuable targets in the action of RRP against CVD. We also examined the biological functions involved in the biological process, molecular function and cellular components. In accordance with the analysis of GSE6054 microarray data of AS disease, the 20 most specifically expressed genes (differentially expressed genes [DEGs]) and the top 10 pathways of DEGs were discovered. Five key pathways, including non-alcoholic fatty liver disease (NAFLD), pathways in cancer and PI3K-Akt signalling pathway were also explored. Amongst these pathways, the top three were the pathways in cancer, MAPK signalling pathway and human T-cell lymphotropic virus infection. The pathways in cancer and PI3K-Akt signalling pathway were found simultaneously in the pathway analysis for CVD on RRP and for AS on microarray data. This study provided a new potential herbal medicine against CVD and has increased the understanding on the molecular mechanisms of RRPmediated protection against CVD, especially AS. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  AS; CVD; RRP; microarray data; molecular mechanism; signalling pathway.

Mesh:

Substances:

Year:  2019        PMID: 31187710     DOI: 10.2174/1389203720666190610161535

Source DB:  PubMed          Journal:  Curr Protein Pept Sci        ISSN: 1389-2037            Impact factor:   3.272


  11 in total

1.  Radix Rehmannia Glutinosa inhibits the development of renal fibrosis by regulating miR-122-5p/PKM axis.

Authors:  Xinhua Liu; Honglan Xu; Yunhua Zang; Weiguo Liu; Xiangbo Sun
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

2.  Virtual screening and network pharmacology-based synergistic mechanism identification of multiple components contained in Guanxin V against coronary artery disease.

Authors:  Bo Liang; Xiao-Xiao Zhang; Ning Gu
Journal:  BMC Complement Med Ther       Date:  2020-11-13

3.  Network pharmacology modeling identifies synergistic interaction of therapeutic and toxicological mechanisms for Tripterygium hypoglaucum Hutch.

Authors:  Dan Zhang; Yizhu Dong; Jintao Lv; Bing Zhang; Xiaomeng Zhang; Zhijian Lin
Journal:  BMC Complement Med Ther       Date:  2021-01-15

4.  System Pharmacology-Based Strategy to Decode the Synergistic Mechanism of GanDouLing for Wilson's Disease.

Authors:  Juan Zhang; Hong Chen; Yuancheng Bao; Daojun Xie; Wenming Yang; Huaizhou Jiang; Ting Dong; Hui Han
Journal:  Evid Based Complement Alternat Med       Date:  2021-01-29       Impact factor: 2.629

5.  Systematic insight into the active constituents and mechanism of Guiqi Baizhu for the treatment of gastric cancer.

Authors:  Ling Li; Xiao-Jie Jin; Jia-Wei Li; Cheng-Hao Li; Shuang-Yan Zhou; Jun-Jie Li; Cai-Qin Feng; Dong-Ling Liu; Yong-Qi Liu
Journal:  Cancer Sci       Date:  2021-03-07       Impact factor: 6.716

6.  Exploring the Molecular Mechanism of Liuwei Dihuang Pills for Treating Diabetic Nephropathy by Combined Network Pharmacology and Molecular Docking.

Authors:  Gaoxiang Wang; Lin Zeng; Qian Huang; Zhaoqi Lu; Ruiqing Sui; Deliang Liu; Hua Zeng; Xuemei Liu; Shufang Chu; Xinhui Kou; Huilin Li
Journal:  Evid Based Complement Alternat Med       Date:  2021-09-13       Impact factor: 2.629

7.  Changes in the Chemical Components of Processed Rehmanniae Radix Distillate during Different Steaming Times.

Authors:  Shujuan Xue; Yu Fu; Xiaoya Sun; Suiqing Chen
Journal:  Evid Based Complement Alternat Med       Date:  2022-02-17       Impact factor: 2.629

8.  A bioinformatics investigation into molecular mechanism of Yinzhihuang granules for treating hepatitis B by network pharmacology and molecular docking verification.

Authors:  Jingyuan Zhang; Xinkui Liu; Wei Zhou; Guoliang Cheng; Jiarui Wu; Siyu Guo; Shanshan Jia; Yingying Liu; Bingbing Li; Xiaomeng Zhang; Miaomiao Wang
Journal:  Sci Rep       Date:  2020-07-10       Impact factor: 4.379

9.  Taohong Siwu Decoction Exerts a Beneficial Effect on Cardiac Function by Possibly Improving the Microenvironment and Decreasing Mitochondrial Fission after Myocardial Infarction.

Authors:  Zhi-Rong Luo; Han Li; Zhong-Xin Xiao; Shui-Jin Shao; Tian-Tian Zhao; Yue Zhao; Fang-Fang Mou; Bo Yu; Hai-Dong Guo
Journal:  Cardiol Res Pract       Date:  2019-12-10       Impact factor: 1.866

10.  Diagnostic Biomarkers and Immune Infiltration in Patients With T Cell-Mediated Rejection After Kidney Transplantation.

Authors:  Hai Zhou; Hongcheng Lu; Li Sun; Zijie Wang; Ming Zheng; Zhou Hang; Dongliang Zhang; Ruoyun Tan; Min Gu
Journal:  Front Immunol       Date:  2022-01-04       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.